IBRX Motley Fool 3 days ago Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month
IBRX MT Newswires 4 days ago ImmunityBio Says Median Overall Survival Not Yet Reached in Phase 2 Glioblastoma Trial
IBRX Business Wire 4 days ago ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
IBRX Insider Monkey 5 days ago Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That” ➖ AI Sentiment Neutral 5/10
IBRX Motley Fool 5 days ago Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses 📈 AI Sentiment Highly Positive 8/10
IBRX Zacks 6 days ago ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission 📈 AI Sentiment Highly Positive 9/10
IBRX Simply Wall St. 6 days ago Insider Favorites: 3 Growth Stocks With Strong Ownership 📈 AI Sentiment Highly Positive 8/10
IBRX Insider Monkey 6 days ago ImmunityBio (IBRX) Rockets on 12th Day, Hits Fresh High 📈 AI Sentiment Highly Positive 9/10